Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.40 |
| ▸ | WNT3A | P56704 | 3/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | GPR183 | P32249 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21807839 | 0.89 | KIF11 (0.45) | KIF11CTNNB1WNT3ANPC1RAB9A | |
| SCHEMBL16307403 | 0.86 | KIF11 (0.34) | KIF11CNR1ALDH1A1HSD17B10TDP1 | |
| SCHEMBL16655842 | 0.81 | KIF11 (0.53) | KIF11CTNNB1WNT3ANOTUMPIK3CA | |
| SCHEMBL4462423 | 0.76 | CNR1 (0.60) | CNR1ALDH1A1HSD17B10TDP1 | |
| SCHEMBL25074748 | 0.74 | KIF11 (0.40) | KIF11CTNNB1WNT3ANOTUMPIK3CA | |
| SCHEMBL28774202 | 0.71 | ALDH1A1 (0.38) | NPC1RAB9AALDH1A1HSD17B10TDP1 | |
| SCHEMBL30204094 | 0.71 | ALDH1A1 (0.38) | NPC1RAB9AALDH1A1HSD17B10TDP1 | |
| SCHEMBL3861110 | 0.70 | AHR (0.50) | KIF11CTNNB1WNT3ANOTUMPIK3CA | |
| SCHEMBL29437166 | 0.69 | CA12 (0.54) | NPC1RAB9AALDH1A1HSD17B10TDP1 | |
| SCHEMBL560493 | 0.69 | CA12 (0.54) | NPC1RAB9AALDH1A1HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4721737-A1 | USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES | Scinnohub Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-20250145635-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LTD (GB) | 2025-04-10 | — | — | US | disclosed |
| US-20250101003-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | LARIO THERAPEUTICS LIMITED (GB) | 2025-03-27 | — | — | US | disclosed |
| WO-2024245143-A1 | USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES | 赛诺哈勃药业（成都）有限公司 | 2024-12-05 | — | — | WO | disclosed |
| EP-4455136-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | Scinnohub Pharmaceutical Co., Ltd. (CN) | 2024-10-30 | — | — | EP | disclosed |
| WO-2024217519-A1 | PYRROLE SULFONYL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 天地恒一制药股份有限公司 | 2024-10-24 | — | — | WO | disclosed |
| EP-4436661-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| EP-4436955-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| CN-118510768-A | Diazasulfinyl structure-containing compounds and their use in medicine | 赛诺哈勃药业（成都）有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
| US-20090239856-A1 | Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors | LABORATOIRES FOURNIER S.A. (FR) | 2009-09-24 | — | — | US | disclosed |
| US-7557122-B2 | Pyrrolopyridine compounds, method of making them and uses thereof | LABORATOIRES FOURNIER S.A. (FR) | 2009-07-07 | — | — | US | disclosed |
| US-20080200495-A1 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof | LABORATOIRES FOURNIER S.A. (FR) | 2008-08-21 | — | — | US | disclosed |
| EP-1686113-A1 | Inhibitors of aspartyl protease | Vertex Pharmaceuticals Incorporated (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1194404-B1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMA (US) | 2006-05-03 | — | — | EP | disclosed |
| US-6878728-B1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040122000-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED. | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145635-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | BCL9, USP9X, BCL9L | KIF11 3082/4885CTNNB1 1141/4885WNT3A 4324/4885 |
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | CACNA1A, CACNA1E, CACNA1S | KIF11 3898/4885CTNNB1 2592/4885WNT3A 2491/4885 |
| US-20040122000-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | KIF11 4568/4885CTNNB1 4592/4885WNT3A 4645/4885 |
| US-20090239856-A1 | Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors | PPARD, PPARA, PPARG | KIF11 4330/4885CTNNB1 3838/4885WNT3A 3989/4885 |
| US-20080200495-A1 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof | LIPG, PCSK9, PNLIP | KIF11 3214/4885CTNNB1 4210/4885WNT3A 4489/4885 |
| US-20250101003-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | CACNA1A, CACNA1E, CACNA1S | KIF11 3528/4885CTNNB1 1142/4885WNT3A 1075/4885 |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | KIF11 4568/4885CTNNB1 4592/4885WNT3A 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.